Patent US4760053A successfully refreshed from Google Patents.
US4760053A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Combination therapy for selected sex steroid dependent cancers
Assignee: Individual
•
Filing: 1986-07-31
•
Granted: 1988-07-26
•
Expires: 2006-07-31
Abstract
Abstract A combination therapy for treatment of selected sex steroid dependent cancers in susceptible warm-blooded animals comprising administering to such animals whose hormone output of their testes or ovaries, respectively, is blocked a therapeutically effective amount of an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis or pharmaceutical compositions thereof wherein the selected sex steroid dependent cancer are, for example, testicular cancer, ovarian cancer, renal cancer or uterine cancer is disclosed.
Inventors
- 👤 Fernand Labrie
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 22:02
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/13
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
83 words
A method of treating selected sex steroid dependent cancers in a warm-blooded animal which comprises administering a therapeutically effective amount of an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis or pharmaceutical compositions thereof to the animal whose hormone output of the testes or ovaries is blocked; wherein the selected sex steroid dependent cancers are testicular cancer, ovarian cancer, colon-rectal cancer, renal cancer, pancreatic cancer, liver cancer, stomach cancer, skin cancer, uterine cancer, brain cancer or larynx cancer.
Claim 2
Independent Claim
83 words
A method of treating selected sex steroid dependent cancers in a warm-blooded animal which comprises administering a therapeutically effective amount of an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis or pharmaceutical compositions thereof to the animal whose hormone output of the testes or ovaries is blocked; wherein the selected sex steroid dependent cancers are testicular cancer, ovarian cancer, colon-rectal cancer, renal cancer, pancreatic cancer, liver cancer, stomach cancer, skin cancer, uterine cancer, brain cancer or larynx cancer.
Claim 3
Dependent Claim
110 words
A method according to claim 1 which for treating testicular cancer, ovarian cancer, colon-rectal cancer, renal cancer, pancreatic cancer, liver cancer, stomach cancer, skin cancer, uterine cancer, brain cancer and larynx cancer comprises administrating a therapeutically effective amount (1) of an antiandrogen or (2) of at least one inhibitor of sex steroid biosynthesis or (3) of an antiandrogen and an antiestrogen or (4) of an antiandrogen and at least one inhibitor of sex steroid biosynthesis or (5) of an antiestrogen and at least one inhibitor of sex steroid biosynthesis or (6) of an antiandroqen and an antiestrogen and at least one inhibitor of sex steroid biosynthesis or pharmaceutical compositions thereof.
Claim 4
Independent Claim
16 words
A method according to any one of claims 1 which further comprises administration of a glucocorticoi<.
Claim 5
Dependent Claim
46 words
A method according to claim 1 wherein the antiandrogen and/or the antiestrogen and/or at least one inhibitor of sex steroid biosynthesis and, if used, the glucocorticoid is/are administered to an animal whose hormone output of the testes or ovaries, has been blocked by surgical removal thereof.
Claim 6
Dependent Claim
82 words
A method according to claim 1 wherein the antiandrogen and/or the antiestrogen and/ or at least one inhibitor of sex steroid biosynthesis and, if used, the glucocorticoid is/are administered to an animal whose hormone output of the testes or ovaries is blocked by chemical means such as by an LH-RH agonist or LH-RH antagonist of which a pharmaceutically effective amount is administered to the animal in association with the antiandrogen and/or the antiestrogen and/or the inhibitor(s) of steroid biosynthesis and/or the glucocorticoid.
Claim 7
Dependent Claim
36 words
A method according to claim 1 which comprises administering the antiandrgoen, the antiestrogen, the inhibitor(s) of sex steroid biosynthesis, the LH-RH agonist or LH-RH antagonist and the glucocorticoid (if applicable) in the form of individual compositions.
Claim 8
Dependent Claim
44 words
A method according to claim 6 wherein the administration of the antiandrogen and/or the antiestrogen is started one day before the administration of the LH-RH agonist or LH-RH antagonist and of the inhibitor(s) of sex steroid biosvnthesis (if used) and the glucocorticoid (if used).
Claim 9
Dependent Claim
21 words
A method according to claim 7 which comprises administering the LH-RH agonist or LH-RH antagonist in the form of parenteral composition.
Claim 10
Dependent Claim
27 words
A method according to claim 1 which comprises administering the antiandrogen, antiestrogen, the inhibitor(s) of sex steroid biosynthesis and the glucocorticoid in the form of oral compositions.
Claim 11
Dependent Claim
13 words
A method according to claim 1 wherein the antiandrogen is 4'-nitro-3'-trifluoromethylisobutyranilide or 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-2,5-dione.
Claim 12
Dependent Claim
65 words
A method according to claim 5 wherein the LH-RH agonist is a nonapeptide or a decapeptide represented by the formula: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-X-Y-L-arginyl-L-prolyl-Z, wherein X is D-tryptophyl, D-leucyl, D-alanyl, iminobenzyl-D-histidyl, 3-(2-naphthyl)-D-alanyl, O-tert-butyl-D-seryl, D-tyrosyl, D-lysyl, D-phenylalanyl or N-methyl-D-alanyl and wherein Y is L-leucyl, N.sup.α -methyl-L-leucyl, D-leucyl, N.sup.α -methyl-D-leucyl, or D-alanyl and wherein Z is glycyl-NHR 1 or NHR 1 wherein R 1 is H, lower alkyl or haloloweralkyl.
Claim 13
Dependent Claim
18 words
A method according to claim 1 wherein aminoglutethimide and/or ketokonazole are used as inhibitors of sex steroid biosynthesis.
Claim 14
Dependent Claim
13 words
A method according to claim 1 wherein the antiestrogen is (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine or LY-117018.
References Cited (Backward Citations)
BE637389A
Cited
US4415553A
Cited
US4024248A
Cited
US4329364A
Cited
US4097578A
Cited
US4071622A
Cited
US4118483A
Cited
US4100274A
Cited
US4094994A
Cited
US4239776A
Cited
US4291028A
Cited
US4292315A
Cited
US4234571A
Cited
US4472382A
Cited
US4386080A
Cited
EP0058481A1
Cited
EP0078158A2
Cited
US4481190A
Cited
US4667014A
Cited
US4530920A
Cited
US4632979A
Cited
US4650787A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-26 | 1992-01-25 | 1992-07-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-26 | 1996-01-25 | 1996-07-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-26 | 2000-01-25 | 2000-07-26 | $7700.00 | Window Closed / Lapsed |